Shire PLC (SHP.L)
LONDON London-listed drugmaker Shire reported a solid start to the year on Thursday with first-quarter earnings up 6 percent despite challenges on several fronts as it works towards a deal to be acquired by Takeda Pharmaceutical .
* Q1 revenue up 5 pct, earnings up 6 pct beat market forecasts
* CEO SAYS REMAINS CONFIDENT IN OUTLOOK AND GUIDANCE FOR HEMATOLOGY FRANCHISE
LONDON, April 26 Shire, the London-listed drugmaker targeted by Takeda Pharmaceutical, reported a 6 percent rise in first-quarter earnings on Thursday, helped by higher product sales and a lower tax rate partially offset by lower gross margins.
April 25 The following bids, mergers, acquisitions and disposals were reported by 2231 GMT on Wednesday:
LONDON/NEW YORK/TOKYO Rare disease specialist Shire said on Wednesday it was willing to recommend a sweetened $64 billion offer from Japan's Takeda Pharmaceutical Co to shareholders, in what would be the biggest acquisition of a drug company since 2000. | Video
* Takeda shares down 7 pct, Shire off 2.8 pct (Adds Shire shares closing down, more on pharma industry M&A)
LONDON GlaxoSmithKline's chief executive said on Wednesday she had no interest in acquiring Shire , the London-listed rare diseases specialist that Takeda Pharmaceutical hopes to buy for some $64 billion.
LONDON, April 25 GlaxoSmithKline's chief executive said on Wednesday she had no interest in acquiring Shire, the London-listed rare diseases specialist that Takeda Pharmaceutical hopes to buy for some $64 billion.
TOKYO Takeda Pharmaceutical Co Ltd's $64 billion bid for London-listed rare disease specialist Shire Plc bolsters its credentials as Japan's most outward facing drugs firm, a mould-breaking image that has been more than a decade in the making.